1715 - In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021

Saturday, October 22, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

MT

Miki Takemura, n/a

Director, Head of Infectious Diseases 5, Laboratory for Drug Discovery and Disease Research
Shionogi & Co., Ltd
Toyonaka, Osaka, Japan
Dee Shortridge, PhD

Senior Director Microbiology
JMI Laboratories
North Liberty, Iowa, United States
CS

Christine M. Slover, PharmD

Shionogi Inc.
Florham Park, New Jersey, United States
CL

Christopher M. Longshaw, PhD

Senior Director, Scientific Affairs EU
Shionogi B.V.
London, England, United Kingdom
RE

Roger Echols, MD

Consultant
Infectious Disease Drug Development Consulting
Easton, Connecticut, United States